A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers

Back to Search
Print
Bookmark Trial

NCT01298544

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Chengxiang Town Hospital
Longan County, Guangxi, 532700, China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
4-5 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects who participated in and completed Wyeth study 0887X 101518.

- Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Vaccination with any licensed or investigational pneumococcal vaccine since completion
of Wyeth study 0887X 101518.


- History of culture proven invasive disease caused by S pneumoniae since the completion
of Wyeth study 0887X 101518.


- Known or suspected immune deficiency or suppression since participation in Wyeth study
0887X 101518.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pneumococcal DiseaseSafety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
NCT04642079
  1. Bristol, Tennessee
  2. Jonesboro, Arkansas
  3. Jonesboro, Arkansas
  4. Inglewood, California
  5. San Diego, California
  6. Miami, Florida
  7. Miami, Florida
  8. Chamblee, Georgia
  9. Sioux City, Iowa
  10. Newton, Kansas
  11. Wichita, Kansas
  12. Bardstown, Kentucky
  13. Lexington, Kentucky
  14. Gulfport, Mississippi
  15. Grand Island, Nebraska
  16. Lincoln, Nebraska
  17. Lincoln, Nebraska
  18. Norfolk, Nebraska
  19. Omaha, Nebraska
  20. Henderson, Nevada
  21. Albuquerque, New Mexico
  22. Binghamton, New York
  23. Dayton, Ohio
  24. Dayton, Ohio
  25. Dayton, Ohio
  26. Medford, Oregon
  27. North Charleston, South Carolina
  28. Bristol, Tennessee
  29. Austin, Texas
  30. Galveston, Texas
  31. San Antonio, Texas
  32. Murray, Utah
  33. Provo, Utah
  34. Salt Lake City, Utah
  35. Salt Lake City, Utah
  36. Salt Lake City, Utah
  37. South Jordan, Utah
  38. Syracuse, Utah
  39. Charlottesville, Virginia
  40. Charlottesville, Virginia
ALL GENDERS
15 Months+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
  1. Kadrina,
  2. Westmead, New South Wales
  3. Nedlands, Western Australia
  4. Nedlands, Western Australia
  5. Brussels,
  6. Edegem,
  7. Jindrichuv Hradec,
  8. Jindrichuv Hradec,
  9. Jindrichuv Hradec,
  10. Pardubice,
  11. Praha 3,
  12. Praha 6,
  13. Sezemice,
  14. Hvidovre,
  15. Tallinn,
  16. Tallinn,
  17. Tallinn,
  18. Tallinn,
  19. Tartu,
  20. Espoo,
  21. Helsinki,
  22. Helsinki,
  23. Järvenpää,
  24. Kokkola,
  25. Oulu,
  26. Pori,
  27. Seinajoki,
  28. Tampere,
  29. Turku,
  30. Milano, Milan
  31. Roma, Rome
  32. Firenze,
  33. Foggia,
  34. Genova,
  35. Haarlem,
  36. Hoofddorp,
  37. Lorenskog,
  38. Oslo,
  39. Stavanger,
  40. Viken,
  41. Bydgoszcz,
  42. Bydgoszcz,
  43. Debica,
  44. Krakow,
  45. Krakow,
  46. Leczna,
  47. Lodz,
  48. Lubon,
  49. Poznan,
  50. Poznan,
  51. Siemianowice Slaskie,
  52. Torun,
  53. Trzebnica,
  54. Warszawa,
  55. Warszawa,
  56. Wroclaw,
  57. Wroclaw,
  58. Bratislava,
  59. Bratislava,
  60. Detva,
  61. Horne Srnie,
  62. Humenne,
  63. Humenné,
  64. Kosice,
  65. Liptovská Osada,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
  1. Isumi-city, Chiba
  2. Fukuoka-city, Fukuoka
  3. Fukuoka-shi, Fukuoka
  4. Osaka-City, Osaka
  5. Ritto-Shi, Shiga
  6. Nagoya-shi, Aichi
  7. Toyota-shi, Aichi
  8. Chiba-shi, Chiba
  9. Funabashi-city, Chiba
  10. Yotsukaido-shi, Chiba
  11. Yotsukaido-shi, Chiba
  12. Fukui-shi, Fukui
  13. Fukuoka-City, Fukuoka
  14. Fukuoka-city, Fukuoka
  15. Iizuka, Fukuoka
  16. Kasuga-city, Fukuoka
  17. Gifu-city, Gifu
  18. Ebetsu Shi, Hokkaido
  19. Sapporo shi, Hokkaido
  20. Sapporo, Hokkaido
  21. Akashi-City, Hyōgo
  22. Kawasaki-shi, Kanagawa
  23. Kumamoto Shi, Kumamoto
  24. Kumamoto-shi, Kumamoto
  25. Kuwana-city, MIE
  26. Nagano-shi, Nagano
  27. Kawachinagano, Osaka
  28. Ureshino-shi, Saga
  29. Hanyu-shi, Saitama
  30. Kumagaya-shi, Saitama
  31. Fuchu-city, Tokyo
  32. Nishitokyo-shi, Tokyo
  33. Setagaya-ku, Tokyo
  34. Setagaya-ku, Tokyo
  35. Shinjuku-ku, Tokyo
  36. Suginami-ku, Tokyo
  37. Kofu-city, Yamanashi
  38. Tsuru-shi, Yamanashi
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
  1. Miami Lakes, Florida
  2. Miami, Florida
  3. Wilmington, North Carolina
  4. Oklahoma City, Oklahoma
  5. Wauwatosa, Wisconsin
  6. Birmingham, Alabama
  7. Mobile, Alabama
  8. Chandler, Arizona
  9. Phoenix, Arizona
  10. Tempe, Arizona
  11. Redding, California
  12. San Diego, California
  13. San Diego, California
  14. Walnut Creek, California
  15. Coral Gables, Florida
  16. Crystal River, Florida
  17. Hialeah, Florida
  18. Jacksonville, Florida
  19. Miami, Florida
  20. Orlando, Florida
  21. Orlando, Florida
  22. Savannah, Georgia
  23. Stockbridge, Georgia
  24. Meridian, Idaho
  25. El Dorado, Kansas
  26. Wichita, Kansas
  27. Wichita, Kansas
  28. Metairie, Louisiana
  29. New Orleans, Louisiana
  30. Elkridge, Maryland
  31. Rockville, Maryland
  32. Saint Louis, Missouri
  33. Norfolk, Nebraska
  34. Omaha, Nebraska
  35. Las Vegas, Nevada
  36. Las Vegas, Nevada
  37. Binghamton, New York
  38. Endwell, New York
  39. Charlotte, North Carolina
  40. Greensboro, North Carolina
  41. Hickory, North Carolina
  42. Raleigh, North Carolina
  43. Raleigh, North Carolina
  44. Rocky Mount, North Carolina
  45. Rocky Mount, North Carolina
  46. Fargo, North Dakota
  47. Cincinnati, Ohio
  48. Cincinnati, Ohio
  49. Cleveland, Ohio
  50. Franklin, Ohio
  51. Warwick, Rhode Island
  52. Little River, South Carolina
  53. Mount Pleasant, South Carolina
  54. Bristol, Tennessee
  55. Nashville, Tennessee
  56. Austin, Texas
  57. Cedar Park, Texas
  58. Fort Worth, Texas
  59. Fort Worth, Texas
  60. Houston, Texas
  61. McKinney, Texas
  62. Pearland, Texas
  63. San Antonio, Texas
  64. Tomball, Texas
  65. Tomball, Texas
  66. Draper, Utah
  67. Salt Lake City, Utah
  68. Salt Lake City, Utah
  69. South Jordan, Utah
  70. Norfolk, Virginia
  71. Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers
Official Title  ICMJE A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518
Brief Summary In 2005, Wyeth conducted study 0887X-101518 (NCT00488826) in which Chinese infants received either Prevenar alone (Group 1), Prevenar given with a Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccine (Group 2) or DTaP alone (Group 3). This follow up study (at least 3 years after the last vaccination) will assess the antibody concentrations in children who previously completed Wyeth study 0887X-101518.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Pneumococcal Disease
Intervention  ICMJE Procedure: Blood draw
One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
Study Arms  ICMJE All subjects
Intervention: Procedure: Blood draw
Publications * Li R, Fang KX, Young M Jr, Zhou X, Chen Z, Liang JZ, Giardina PC, Scott DA. Long-term antibody persistence study (3 years after last dose) of the 7-valent pneumococcal conjugate vaccine in young children in China. Vaccine. 2016 Oct 17;34(44):5359-5365. doi: 10.1016/j.vaccine.2016.08.070. Epub 2016 Sep 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 13, 2012)		335
Original Estimated Enrollment  ICMJE
 (submitted: February 16, 2011)		400
Actual Study Completion Date  ICMJE March 2011
Actual Primary Completion Date March 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female subjects who participated in and completed Wyeth study 0887X 101518.
  • Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria:

  • Vaccination with any licensed or investigational pneumococcal vaccine since completion of Wyeth study 0887X 101518.
  • History of culture proven invasive disease caused by S pneumoniae since the completion of Wyeth study 0887X 101518.
  • Known or suspected immune deficiency or suppression since participation in Wyeth study 0887X 101518.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 4 Years to 5 Years   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01298544
Other Study ID Numbers  ICMJE B1841009
6114A1-4001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP